- Home
- SPFI vs ASMB Comparison
SPFI vs ASMB Comparison
Compare SPFI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | ASMB |
|---|---|---|
| Founded | 1941 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.0M | 553.6M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SPFI | ASMB |
|---|---|---|
| Price | $39.56 | $33.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $41.75 | ★ $43.40 |
| AVG Volume (30 Days) | 56.5K | ★ 138.9K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | ★ 36.91 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $205,251,000.00 | $37,191,000.00 |
| Revenue This Year | $13.52 | $33.33 |
| Revenue Next Year | $6.28 | N/A |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | 11.60 | ★ 31.30 |
| 52 Week Low | $30.01 | $7.75 |
| 52 Week High | $42.38 | $39.71 |
Technical Indicators
Market Signals| Indicator | SPFI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 48.81 |
| Support Level | $40.60 | $31.51 |
| Resistance Level | $41.50 | $38.99 |
| Average True Range (ATR) | 0.92 | 2.15 |
| MACD | -0.10 | -0.32 |
| Stochastic Oscillator | 33.12 | 33.29 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.